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Abstract: The quality and relevance of nanosafety studies constitute major challenges to ensure
their key role as a supporting tool in sustainable innovation, and subsequent competitive economic
advantage. However, the number of apparently contradictory and inconclusive research results has
increased in the past few years, indicating the need to introduce harmonized protocols and good
practices in the nanosafety research community. Therefore, we aimed to evaluate if best-practice
training and inter-laboratory comparison (ILC) of performance of the 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay for the cytotoxicity
assessment of nanomaterials among 15 European laboratories can improve quality in nanosafety
testing. We used two well-described model nanoparticles, 40-nm carboxylated polystyrene
(PS-COOH) and 50-nm amino-modified polystyrene (PS-NH2). We followed a tiered approach
using well-developed standard operating procedures (SOPs) and sharing the same cells, serum and
nanoparticles. We started with determination of the cell growth rate (tier 1), followed by a method
transfer phase, in which all laboratories performed the first ILC on the MTS assay (tier 2). Based on
the outcome of tier 2 and a survey of laboratory practices, specific training was organized, and the
MTS assay SOP was refined. This led to largely improved intra- and inter-laboratory reproducibility
in tier 3. In addition, we confirmed that PS-COOH and PS-NH2 are suitable negative and positive
control nanoparticles, respectively, to evaluate impact of nanomaterials on cell viability using the
MTS assay. Overall, we have demonstrated that the tiered process followed here, with the use of
SOPs and representative control nanomaterials, is necessary and makes it possible to achieve good
inter-laboratory reproducibility, and therefore high-quality nanotoxicological data.
Keywords: nanosafety; cytotoxicity; inter-laboratory comparison; best practice; training
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1. Introduction
Within the last 20 years, there has been a tremendous increase in numbers of publications
on nanomaterial (NM) toxicity, many of which report inconclusive and controversial results, often
apparently conflicting. This has generated a wide debate on the quality and relevance of published
papers in nanosafety, including—for instance—a discussion opened up by the Nature Nanotechnology
journal [1,2], which was followed by several commentaries and other examples [3,4]. A similar
discussion about the reliability and reproducibility of experimental data has also been raised for science
in general [5–7], as it was demonstrated for pre-clinical studies on cancer [8]: using in-house data
trying to validate the published results, the authors found that at most only 25% were in line with
published data. Efforts to adhere to the biological models as used in the original publications did not
improve these results. Conversely, reproducible results were also transferable between models [8].
Largely, discrepancies arise from honest mistakes and flawed statistics, but a recent focus on bad
practices and fraud in science has also uncovered instances of the latter [9,10]. Most of the published
research has been performed in research laboratories, e.g., at universities, which usually do not adhere
to good laboratory practice (GLP) or similar standards. GLP was developed specifically out of an
experience of data manipulation and fraud in toxicological contract research [11–13]. In regulatory
toxicology, adherence to GLP, Organization for Economic Cooperation and Development (OECD)
guidelines and International Organization for Standardization (ISO) standards is therefore paramount.
Applying similar standards to the existing literature on nanotoxicology by checking publications against
a defined set of criteria, such as physico-chemical material characterization or detailed descriptions of
the assays applied, including solid statistical data evaluation, resulted in approximately 68% [14] to
90% [15] of the studies being rejected.
Even if it sounds trivial, it has to be stressed that in nanotoxicology all steps from synthesis route
to nanoparticle (NP) sample preparation for testing and every step in-between will have an effect on the
outcome of the experiments. NMs may become altered throughout all these processes. For biological
testing, the dispersion of NMs into media has two crucial aspects, the type of dispersion [16] and the
composition of the media [17]. The energy used for the dispersion can, for instance, passivate the surface,
influence the agglomeration state and cause dissolution of molecules into ions [18]. Liquid media and
biological fluids can influence the same parameters and, importantly, the presence of proteins and
other biomolecules leads to the formation of a biocorona on the surface of the NMs [19]. The impact of
the corona on NP-cell interactions is demonstrated by the differential cytotoxicity of NPs in the absence
or presence of serum, as a general paradigm for all NMs, such as for instance silica [20,21], positively
charged NPs [22], carbon nanotubes [23] and graphene oxides [24]. While under realistic exposure
conditions in biological fluids the NMs are passivated by the presence of this layer of biomolecules
from the surrounding environment, in artificially simplified laboratory conditions, such as serum-free
medium, the bare surfaces of NMs can adhere so strongly to the cell surface that they generate damage
and other biological processes. Importantly, even the amount and identity of proteins present affects
NP outcome on cells [25–27], opening up new challenges for determining realistic exposure scenarios.
Other unique features of NMs affecting the outcomes of toxicity testing in comparison to standard
chemicals include the interference of the NM itself with the testing method: NMs can adsorb and
scatter light, interfering with tests based on absorbance, luminescence and fluorescence detection.
Furthermore, NMs can also adsorb the reagents used for the tests on their surface, thus causing
artefacts that could be misinterpreted for signals [28]. These are just some examples of the many
unique features of materials at the nanoscale, which have caused the need for the development of new
methods and procedures, as well as specific laboratory practices, in order to be able to generate robust
and reproducible data in nanosafety.
These issues are the main reasons why most studies are incomparable [4]. To achieve improved
comparability and reproducibility, protocols have to be harmonized and standardized. Moreover, there
is a need for the development of alternative testing strategies, as the vast possibilities of engineering
NMs would result in a high number of animal studies if current regulatory protocols were to be
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followed. Animal studies are not only costly, time consuming and ethically fraught; the legislation of
cosmetics in the European Union already prohibits this type of testing. Alternative in vitro testing
might be a useful tool to prioritize animal testing to NMs of concern. In addition, these methods might
be used during R&D to eliminate substances with hazardous properties. Standardization of in vitro
procedures requires examining all involved materials and specifying every single step in a protocol.
For instance, cell lines have to be identical [29] and free of mycoplasma [30], and even the way how
cells are seeded into a multi-well plate has consequences on the test result [31].
In this study, an inter-laboratory comparison (ILC) study among 15 European research laboratories
was organized to test how easy it was to generate reproducible data on NP-induced toxicity
using standard operating procedures (SOPs), and define processes to enhance the proficiency of
nanosafety research laboratories in achieving reliable NM toxicity data. We have employed the
in vitro 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) cytotoxicity assay of the tetrazolium salt reduction-type [32] as a benchmark, which has been
addressed before by other ILC consortia consisting of 8 [33], 5 [34] or 6 [35] independent laboratories.
Briefly, SOPs were generated by laboratories with previous experience on this assay, as well as
in working according to the principles of GLP. The SOP for the MTS assay, including the 96-well
plate lay-out and performance criteria, was in agreement with Rösslein et al. [36] and the recently
published ISO 19007:2018 standard [37]. Cells, serum and NPs, all from the same batches, were shared
among the participating laboratories across Europe, which were enrolled based on the outcome of a
first tier on cell culturing proficiency. The second tier was a first MTS inter-laboratory comparison
study. Its results, followed by a questionnaire sent to all participants to collect more information
on how the procedure was followed, clearly highlighted the need for further optimization of the
developed SOP, but also the need of a more precise training in executing this kind of standardized
testing. After training of the participants, the third tier consisted of a new round of the MTS assay
using the revised SOP. The final results showed a strong reduction in the variability within and
across laboratories. Furthermore, our data endorsed the potential of amine-modified polystyrene
nanoparticles (PS-NH2) and carboxyl-modified polystyrene nanoparticles (PS-COOH) as positive and
negative control nanomaterials, respectively, for cytotoxicity assessment using the MTS assay.
2. Materials and Methods
2.1. Recruitment of Laboratories
Laboratories involved in nanosafety research across Europe that were (associated) partners of
the QualityNano Research Infrastructure consortium were invited to the inter-laboratory comparison
study. Before the start of the study, an online questionnaire was sent out to the candidate laboratories
to inquire about and evaluate them against criteria mentioned in ISO/IEC 17043:2010 ‘Conformity
assessment—general requirements for proficiency testing’ [38], including: experience in biological
assessments of NMs or in performing tests similar to the proposed method and/or cell model; the
availability of the technical requirements for accommodation, environmental conditions and endpoint
measurements; high quality standards for biological testing implemented, such as good cell culture
practice or GLP; and trained personnel. In total, 15 laboratories from academia (33.3%), research
organizations (60.0%) and industry (6.7%) joined the study. The majority of them were not familiar
with the requested high-quality standards that have been developed primarily for regulatory testing
or method validation. Moreover, the test performers had varying qualifications (lab technician,
PhD student or post-doctoral scientist) and a varied numbers of years of experience in biological testing
(from a few months to over 20 years). In most cases, they were not trained in the proposed SOPs.
2.2. Choice of Cytotoxicity Test and Materials Used
As mentioned above, we selected the in vitro MTS cytotoxicity assay as a benchmark assay to
evaluate and improve laboratories’ proficiency. The CellTiter 96® Aqueous One assay (Promega,
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Leiden, The Netherlands) used in this study has been identified as superior to other cell viability
assays for NP assessment [39]. The assay has originally been developed by Tim Mosmann [32] for
the measurement of cell viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT). Soluble tetrazolium salts, including 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS), have later been developed, of which the tetrazolium ring
is reduced by cellular nicotinamide adenine dinucleotide (phosphate)-dependent oxidoreductase
enzymes in the presence of an intermediate electron acceptor (phenazine ethosulfate), to form a
formazan derivative that is quantified in a spectrophotometer. The product therefore reflects the
metabolic activity and by extension viability of cells, and, hence, can be used to determine a toxic
dose of a substance. Information on the cytotoxicity of a substance in alternative methods using cell
culture is a crucial first screening step to any more detailed investigation, or as part of a safe-by-design
approach. Test methods to assess the in vitro cytotoxicity of medical devices have been described in
ISO 10993-5:2009 [40]. A standard specifically dedicated to nanomaterials using the MTS assay as an
in vitro cytotoxicity assay has more recently been published [37].
The human A549 alveolar epithelial cell line was chosen as a cell type representing the respiratory
route of exposure and a major site of deposition of small nanoparticles [41,42]. Moreover, this cell
model is widely used in nanosafety laboratories and easy to maintain, and therefore suitable for
standardization among different laboratories.
Alternative methods for toxicity testing require substances with known potential, either positive
or negative control substances, which are crucial as quality controls in SOPs. So far, several NM controls
have been suggested for in vitro nanoparticle toxicity studies, including tungsten carbide-cobalt [43]
as positive, and barium sulfate [44] and carboxylated nanodiamonds [45] as negative controls. As is
true for chemicals, any NM that would be used as a control for a specific assay needs to be thoroughly
characterized with respect to its physico-chemical properties, and its performance in this assay also
needs to be well described. However, for NMs special care has to be taken, because of possible
batch-to-batch variation, contamination and long-term stability [46]. In our study, we have selected
50-nm amine-modified polystyrene NPs (PS-NH2) and 40-nm carboxyl-modified polystyrene NPs
(PS-COOH), which are known to form stable dispersions when diluted in cell culture medium [47–49].
Furthermore, their impact on cells has been characterized in detail [22,26,48,50–52]. Thus, they
constituted ideal candidates as starting materials for this ILC study.
2.3. Standardization Procedures and SOP Development
Standard operating procedures for cell culturing and cell growth rate determination (tier 1), and
cytotoxicity assessment using the MTS assay (tier 2 and 3) were adopted from existing protocols,
and adapted to implement the spirit of Good Cell Culture Practice [53] and GLP [13], and to be in
line with the ISO 19007:2018(E) standard [37]. Forms for detailed registration of performance of
the protocol steps were prepared and filled in by the partner laboratories, to make it possible to
formulate corrective actions in case of deviations in a laboratory’s results. For data analysis and
reporting, spreadsheet (Microsoft Excel) templates and web forms were prepared and distributed
to the laboratories. These enabled automated calculations and immediate evaluation of compliance
with the test acceptance criteria as formulated in the SOPs. After a first ILC on the MTS assay (tier 2)
with the developed SOPs, further changes were made to the MTS assay SOP, and forms based on the
feedback from the participating laboratories through an online questionnaire. The optimized SOPs
and the spreadsheet templates are available in Supplementary Materials.
To enhance standardization in cell growth and test performance, all laboratories used the most
critical materials, such as fetal bovine serum and test NPs from a centrally held stock prepared
at one location. Fresh aliquots were shipped to the laboratories prior to the start of the studies.
In addition, identical frozen cell stocks of the human A549 alveolar epithelial cell line were obtained
by the participating laboratories from a central laboratory, which purchased a parent cell line (ATCC,
CCL-185, passage number 82) and subcultured the cells up to a master cell bank (passage number
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88). A harmonized SOP for thawing, freezing and subculturing of the A549 cell line, and testing for
mycoplasma contamination according to an in-house protocol as an essential quality control before
freezing the cells, was developed and used by the study partners to generate their own working cell
bank. Other critical reagents, such as cell culturing reagents, MTS reagent and staurosporine were
used from the same supplier by the laboratories.
2.4. Nanoparticles and Chemical Control
PS-NH2 (50 nm) and fluorescently labelled PS-COOH (40 nm) were purchased from Bangs
Laboratories Inc. (Fishers, IN, USA; catalogue number PA02N) and Molecular Probes (ThermoFisher
Scientific, Bio-Sciences, Dublin, Ireland; catalogue number F8795), respectively. Aliquots of diluted NPs
(10 mg/mL) in milliQ water (resistivity of 18.2 mΩ.cm at 25 ◦C) were prepared centrally, distributed
among all participants, and stored at 4 ◦C. Dispersions of the NPs of 100 µg/mL in complete cell culture
medium (CCM) containing minimal essential medium with GlutaMAX™ (Gibco®, Life Technologies,
Paisley, UK), supplemented with 10% (v/v) non-heat inactivated fetal bovine serum (FBS; Gibco®,
Life Technologies, Paisley, UK), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco®, Invitrogen,
Paisley, UK) were prepared by each laboratory. This was done by pipetting 20 µL of the NP stock
suspensions in 1980 µL medium and mixing on a vortex for 30 s.
Staurosporine (Proteinkinase, Biaffin GmbH & Co., KG, Kassel, Germany; catalogue number
PKI-STSP-001) was used as a positive chemical control to serve as an internal control of the biological
cell response and MTS assay performance. As this compound was observed to become instable and
lose its activity during transport and storage when prepared as solution, all laboratories were asked to
purchase their own lot of lyophilized powder from the same company and with the same batch number.
A stock solution of 1 mM staurosporine was prepared by dissolving the powder in 214 µL dimethyl
sulfoxide (DMSO) and mixing on a vortex, followed by immediate further dilution to 2140 µL DMSO.
Aliquots of 50 µL stock solution were stored at −80 ◦C without loss of activity for at least 6 months,
and a fresh tube was thawed for each experiment. Solutions of 1000 nM staurosporine were prepared
in complete CCM containing 1% milliQ water to ensure identical vehicle to the NPs. Details on the test
item preparations are described in the SOP for the MTS cytotoxicity assay (Supplementary Materials).
2.5. Cell Culture and Exposure
Human A549 alveolar epithelial cells were maintained in complete CCM without antibiotics.
The cells were subcultured every 3–4 days when the cell monolayer reached 70–80% confluence,
with medium renewal after 2 days. Cells were used for testing up to passage number 20, to ensure
equally low passage numbers among experiments and laboratories. Cells were used at >90% viability.
Details are in the SOP for A549 cell culturing in Supplementary Materials.
Cell growth curves were obtained as detailed in the SOP for assessment of A549 cell growth rate
and viability (Supplementary Materials) by determining the cell number and viability by trypan blue
exclusion at 24 h, 48 h and 72 h after seeding.
Assessment of NP-induced cytotoxicity by the MTS assay was performed in 96-well plates, in
which 200 µL of cell suspension were seeded per well, followed by 24 h incubation at 37 ◦C, 5% CO2 to
allow for cell adhesion prior to exposure to the test items. The dosing plate layout, shown in Figure S1,
contained three replicate series of 6 concentrations of either the PS-NH2 or PS-COOH NPs (0; 1; 10;
25; 50 and 100 µg/mL) and 6 concentrations of staurosporine (0; 62.5; 125; 250; 500; and 1000 nM) as a
positive chemical control, in addition to six replicate wells for each of 4 assay controls, according to
Rösslein et al. [36]. Triplicate dilution series of the NPs and staurosporine were each started from a
separate preparation of the highest test concentration, in order to estimate within-laboratory variability
in the preparation. Dose series of the test items were obtained by serial dilutions in complete CCM
supplemented with antibiotics, and containing 1% milliQ water to ensure identical vehicle in each well.
Assay controls consisted of untreated cells in complete CCM with 1% milliQ water, blank wells (no
cells) containing complete CCM with 1% milliQ water, and blank wells (no cells) containing the highest
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test concentrations of the NPs and staurosporine to control for potential interference with the assay
read-out measurement. Cells were exposed by the removal of the medium from each well and transfer
of 100 µL of the chemical and NP doses from the dosing plate, and, again, incubated for 24 h. All details
and plate layouts can be found in the SOP for the MTS cytotoxicity assay (Supplementary Materials).
2.6. MTS Assay
At the end of the incubation of cells with the NPs and staurosporine doses, the medium was
removed from each well and replaced with 150 µL of diluted CellTiter 96® AQueous One Solution
Reagent containing MTS and the electron coupling reagent phenazine ethosulfate (Promega, Leiden,
The Netherlands). Cell plates were incubated at 37 ◦C and 5% CO2 for 1 h, to allow for bioreduction of
the tetrazolium compound to a colored, soluble formazan product. The absorbance of the product
at 490 nm, which is directly proportional to the number of living cells in culture was recorded using
a spectrophotometer. Measurements were performed in the presence of the cells, and—after SOP
optimization—after transfer of 100 µL of the colored reagent from the cell plate into a new 96-well
plate, to ensure absorbance read-out in the linear dynamic range relevant to the Lambert-Beer law.
2.7. Statistical Data Analysis and Proficiency Testing
At least 3 independent runs executed on different days using cell cultures of different passage
numbers were performed for cell growth rate determination (tier 1) and the MTS assay (tier 2 and 3).
An initial analysis of the raw data was done by the individual laboratories using a spreadsheet calculation
template enabling immediate evaluation of compliance with the test acceptance criteria mentioned in
the SOPs, as well as automated data analysis and plotting (Supplementary Materials). Only data sets
from fully acceptable tests were considered valid to be included in the final statistical analysis.
In the determination of cell growth rate, the total cell counts and percentages of cell viability
were calculated, based on the live and dead cell numbers. A curve presenting the live cell counts at
different growth times (24, 48 and 72 h) was used for exponential fitting (Figure S2). The prefactor of
the exponential power from the resulting equation indicated the relative growth rate (doublings per
hour), and was used to calculate the cell doubling time (hours).
In a run of the MTS assay, the percentage cell survival was calculated as the fraction of cells that
remained viable after treatment, by subtracting the average background absorbance of medium blank
wells (Figure S1, column 7) from each raw absorbance value, and normalizing the resulting values
to the average absorbance of untreated cells. The triplicate values from a single dose were used to
calculate a mean value and standard deviation (SD).
The statistical analysis of the MTS assay data from all laboratories was automated using in-house
programming in R software [54]. Fitted sigmoidal curves with the upper limit fixed to 100 and lower
limit to 0 were generated per run based on the dose-response data, and used to calculate the effective
concentrations causing 30% (EC30, for staurosporine) or 50% (EC50, for PS-NH2) inhibition of cell
viability. For curve fitting the R package drc was used [55] and the four-parameter logistic model with
parameters b, c, d, e:
f (x, (b, c, d, e)) = c + (d − c)/(1 + exp[b (log(x) − log(e))] (1)
Parameter e corresponds to the EC30 or EC50, whereas parameter b denotes the relative slope
around e. The logistic function is symmetric around e. Examples of resulting dose-response curves per
run of two different laboratories are shown in Figure S3.
For proficiency testing by inter-laboratory comparisons, statistical methods according to ISO
13258:2005(E) were followed in this study. More specifically, a robust statistical approach described in
algorithm A [56] was applied to calculate robust values of the mean and SD of cell doubling times,
% cell survival per dose, and EC30 (or EC50) from at least 3 independent runs reported by the individual
participants in a round of the proficiency testing scheme. Next, the robust overall mean and SD
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from the data of all laboratories were calculated, starting from the robust mean data per lab using
the algorithm A. Additionally, for the MTS data, based on the robust within-laboratory SD for each
dose or EC30 (or EC50), a robust overall SD* was calculated using algorithm S [56], which yields a
robust pooled value of the SD values, to which it is applied. Intra- and inter-laboratory biases were
interpreted on the basis of overall mean and SD values derived from all laboratories. We concluded
that a laboratory was proficient if the robust within-laboratory mean value did not exceed the overall
mean with more than 2-fold the overall SD. Similarly, if the SD values of one laboratory were within
the range of twice the overall SD*, then the laboratory bias at the individual dose or EC30 (or EC50)
level was considered acceptable.
Finally, a coefficient of variation (CV) was calculated to evaluate the reproducibility of assay
performance as: (robust SD/robust mean) × 100%. Variability of biological test results within or
between laboratories was considered acceptable if CV < 30%.
3. Results
3.1. Determination of Cell Growth Rate (Tier 1)
In a first tier of the study, an SOP on A549 cell culturing and an SOP on determination of cell
growth rate and viability (Supplementary Materials) were used by the 15 participating laboratories, to
assess variability in the cell growth characteristics. Cell cultures for independent runs were started
from independent cell vials of the working cell bank and tested for the absence of mycoplasma
infection using in-house procedures. Relative cell viability was tested by trypan blue exclusion and
was observed to fulfil the acceptance criterion (>90%) mentioned in the cell culturing SOP in the
different laboratories. The mean cell doubling time derived from individual cell growth curves of
all laboratories was 24.9 ± 2.4 h, and showed good agreement within and between the participating
laboratories. Each laboratory produced at least two independent measurements, resulting in a mean
doubling time within the boundaries of the overall mean ± 2SD, which indicated that they were all
proficient in cell culturing (Figure 1). The largest variability was observed within laboratory 15, which
obtained a mean cell doubling time of 28.4 ± 3.2 h.
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independent runs (indicated with open circles) were performed in each laboratory to determine the cell
doubling time. The mean of each lab (filled circles), and overall mean (N = 15; black solid line) with 1-,
2- or 3-fold of the overall standard deviation (SD) (black dotted lines) are indicated.
3.2. Assessment of Laboratories’ Inherent Proficiency in Performing the In Vitro MTS Assay (Tier 2)
After benchmarking and confirming the proficiency of the laboratories in their cell culturing
performance, they were enrolled in a second tier of the inter-laboratory comparison study involving
the transfer of the SOP on the MTS assay. Here, we aimed to evaluate the inherent proficiency of
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each participating laboratory, and identify critical phases in the SOP that introduce bias in testing, to
allow further optimization of the SOP. For this study tier, the laboratories performed independent runs
using cells of different passage number from the same working cell bank vial. Results on cytotoxicity
assessment of the positive chemical control staurosporine showed that eight out of 15 laboratories
reported on at least three independent and valid runs, based on assessment against the test acceptance
criteria mentioned in the SOP. For the tests with PS-COOH and PS-NH2, however, only five and four
out of 15 participating laboratories, respectively, were able to generate at least three valid runs (Table 1).
The most frequent reason for this low rate of valid runs was a deviation of more than 15% in the
absorbance values from triplicate cultures treated with zero dose of the test item (staurosporine or NPs;
Figure S1, row B), as compared to untreated cultures (Figure S1, column 6). This can be attributed to
the differences in seeded cell numbers or cell densities in the respective wells of the multi-well plate,
which may have multiple causes, such as the poor resuspension of cells while seeding, inaccurate
pipetting volumes, wrong pipetting technique, etc. Furthermore, about half of the laboratories observed
interference of the PS-NH2 with the absorbance read-out for more than 15% compared to blank wells
containing no NPs, which was set as a limit for acceptance of the test. More detailed data investigation
revealed that this was mainly due to high variability (CV >30%) between replicate wells of the NP
blank within these laboratories.
Table 1. Compliance of laboratories with the acceptance criteria of the 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cytotoxicity assay. The number of
compliant laboratories compared to the total number of laboratories is indicated per test item.
Acceptance Criteria Staurosporine PS-COOH PS-NH2
- Average absorbance values of NP blank deviating <15% from
medium blank (no NP interference) n/a
1 14/15 8/15
- Blank replicate values, CV 2 <30% 15/15 15/15 15/15
- Blank-corrected absorbance values >0.1 15/15 15/15 14/15
- Blank-corrected absorbance values, CV <30% 12/15 14/15 6/15
- Average absorbance values at zero dose deviating <15% from
non-treated cells 8/15 6/15 7/15
- % cell survival <70% for at least one concentration of positive
chemical control (staurosporine) 13/15 14/15 13/15
≥ three valid and independent runs 8/15 5/15 4/15
1 n/a, not applicable; 2 CV, coefficient of variation.
The dose-response data of staurosporine and NP-induced cytotoxicity in A549 cells were evaluated
using robust statistical methods. Examples of dose-response data from single laboratories are shown
in Figure S3. Dose-dependent decrease in percentage cell survival was observed for staurosporine and
PS-NH2, whereas PS-COOH did not affect cell viability as expected. Intra- and inter-laboratory biases
were calculated, while including either all data from both valid and non-valid runs of all laboratories
(Figure S4), or only the data from the laboratories with at least three valid runs (Figure 2).
Overall variability in the dose-response data, represented by the SD of the mean % cell survival
of all laboratories and the SD*, which represents a pooled value of the within-laboratories’ SD, was
observed to decrease when non-valid runs were discarded, indicating improved inter-laboratory
reproducibility. At the same time, the number of laboratories with an intra-laboratory bias exceeding
the overall mean plus 2-fold of the overall SD decreased (Figure 2 vs. Figure S4). These findings
highlight the need to apply acceptance criteria as quality measures to the biological test performance
to enhance reproducibility of results and hence standardization.
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Figure 2. Intra- and inter-laboratory biases for percentage cell survival determined using the MTS
assay based on valid runs (tier 2). Mean percentage cell survival per dose and per laboratory compared
to the overall mean and SD (left panels), as well as SD of percentage cell survival per dose and per
laboratory compared to the overall SD* (right panels) are shown for (A,B) staurosporine (N = 8),
(C,D) carboxyl-modified polystyrene nanoparticles (PS-COOH) (N = 5) and (E,F) amine-modified
polystyrene nanoparticles (PS-NH2) (N = 4). Horizontal bars (left panel) indicate overall mean values
of percentage cell survival, while grey shaded areas indicate the distances from the overall mean
corresponding to 1-, 2- or 3-fold the overall SD (left panels) or SD* (right panels).
To further assess the intra- and inter-l boratory bias of toxicity values obtained in the different
laboratories, EC30 and EC50 values were derived from the fitted dose-response curves resulting from
cell exposures to staurosporine and PS-NH2, respectively. Althoug an EC50 value can usually be
derived m e accur tely than an EC30 value, approximat ly half of the participants were not able to
observe 50% inhibition of cell viability at 1000 nM staurosporine. Therefore, the EC30 of staurosporine
was reported and compared, since it corresponds to the threshold value for concluding on cytotoxicity
according to ISO 10993-5:2009 [40]. Wh n both non-valid and valid runs were taken into accou t,
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mean fitted EC30 of 329.7 ± 182.0 nM staurosporine and EC50 of 76.2 ± 20.4 µg/mL PS-NH2 were
observed, with respective CVs of 55.2% for staurosporine and 26.8% for PS-NH2. These effective
concentrations changed to an EC30 of 261.0 ± 121.1 nM staurosporine and EC50 of 76.2 ± 12.9 µg/mL
PS-NH2 (Figure 3A,C) when only valid runs were considered, resulting in decreased CVs of 46.4% for
staurosporine and 16.9% for PS-NH2, respectively. By excluding non-valid data the overall variability
SD* of the EC50 values determined for PS-NH2 exposed cells was again decreased (10.6 for non-valid
and valid data, vs. 6.9 for valid data; Figure 3D), indicating that intra-laboratory performances were
also improved. In contrast, this improvement was not observed for EC30 determinations in tests with
staurosporine (SD* of 78.7 vs. 84.6; Figure 3B), which, in general, showed lower reproducibility within
and between laboratories. The latter is in agreement with the low stability of staurosporine in solution
we observed during the study, and, therefore, other stable compounds, such as cadmium sulfate [34,37]
are more suitable as a positive control.
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Figure 3. Intra- and inter-laboratory biases for effective concentration causing 30% inhibition of cell
viability (EC30) and effective concentration causing 50% inhibition of cell viability (EC50) values
determined using the MTS assay (tier 2). Mean values for EC30 and EC50 per laboratory compared to
the overall mean and SD (left panels), as well as SD of EC30 and EC50 values per laboratory compared
to the overall SD* (right panels) are shown for (A,B) staurosporine (N = 15 for all runs, N = 8 for valid
runs) and (C,D) PS-NH2 (N = 15 for all runs, N = 4 for valid runs). Horizontal bars (left panel) indicate
overall mean values of percentage cell survival, while grey shaded areas indicate the distances from the
overall mean corresponding to 1-, 2- or 3-fold of the overall SD (left panels) or SD* (right panels).
Although variabilities were, in most cases, decreased when only valid results were included, these
were still high (at the limit of what is acceptable) and warranted further investigation of possible causes
and refinement of the benchmarking process. Thus, we examined in more detail if these first MTS
experiments could highlight sensitive steps in the applied procedure, which introduced variability in
the reported outcomes. This was done by collecting feedback on the interpretation of the SOP and
performance of the MTS test by the participating laboratories using an online questionnaire. A list of
critical steps that were reported in this survey is included in Table 2. These steps, including accurate
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pipetting volumes and seeding cell densities, were found to be quite similar to those already described
in Rösslein et al. [36] and Elliott et al. [34].
Table 2. Critical steps in the standard operating procedure (SOP) for the MTS cytotoxicity assay.
Following the analysis of the first data obtained for cells treated with staurosporine, PS-NH2 and
PS-COOH, and the collection of responses of the participating laboratories to an online questionnaire
on SOP interpretation and test performance, sensitive steps in the SOP that could generate and explain
the observed variability of outcomes have been individuated.
Protocol Step Critical Phase
All steps
- Verification of pipets and instruments
- Use of single vs. multi-channel pipets
- Pipetting technique
- Adherence to timings stated in the SOP
Preparation and storage of staurosporine stock - Dissolution of lyophilized product
Preparation of staurosporine working solution - Low pipetting volume
Preparation of NP dilutions in cell culture medium
- Low pipetting volume
- Dispersion protocol
Preparation of dosing plate - Different pipetting volumes
Plating cells
- Use of antibiotics-free cell culture medium
- Cell counting method
- Homogeneous suspension of cells
- Edge effects
Exposure to test item
- Removal of medium from cultures
- Homogeneous suspension of test items
- Application of test solutions onto cultures
MTS assay
- Removal of medium from cultures
- Air bubbles
- Precipitate of MTS reagent
- Transfer of MTS reagent for read-out
- Spectrophotometer specifications
Based on a thorough examination of the data and statistical analysis, and the collected feedback
on critical phases in the test performance, we further optimized the SOP of the MTS cytotoxicity assay
(available in the Supplementary Materials). One aspect concerned the possible contribution of cells
and NPs present during assay read-out to variability in the absorbance values, frequently causing them
to exceed a value of 2.0, which is outside the linear dynamic range that is relevant to applying the
Lambert-Beer law, as previously suggested by Xia et al. [33]. Therefore, in the revised SOP, laboratories
were asked to read out the assay plates in the presence and absence of cells. Other critical steps in the
test performance which cannot simply be addressed in the SOP, such as the verification of instruments
or pipetting techniques, constituted major challenges to be faced in this field of research, to ensure
quality of results. This led us to organize a focused training to resolve these issues. Additionally, the
majority of participating laboratories indicated that they were not familiar with the principles of an
inter-laboratory comparison, as exemplified by the submission of a large number of non-valid data.
Training was thus held by well documented instructions and a teleconference to introduce the relevant
principles of GLP and proficiency testing, to transfer the optimized SOP and quality criteria, and to
discuss in detail good practices for enhancing the test performance. Subsequently, the final tier of the
ILC study was launched.
3.3. Laboratories’ Proficiency in Performing the In Vitro MTS Assay After Training (Tier 3)
In the third and final tier of the study, six laboratories were enrolled, of which five also had
participated in the first phase (tier 1 and 2) with involvement of the same operator, and four had not
been able to provide a full set of valid data in the second tier. The other laboratories dropped out
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mainly because of a shift or lack of resources at the time of the last tier. The participating laboratories
were provided with fresh FBS and NPs, and used the optimized MTS assay SOP. All laboratories sent
in data on three independent, valid runs performed on cells of different passage number from the same
working cell bank vial. The dose-response data were evaluated for intra- and inter-laboratory biases,
similar to the statistical analyses in tier 2 (Figures S5–S7). In Table 3, the mean ± SD values of EC30
and EC50 obtained by the six laboratories involved in the study before and after training are presented,
together with the overall mean ± SD values of all laboratories.
Table 3. Comparison of intra- and inter-laboratory biases for EC30 and EC50 values before (tier 2)
and after (tier 3) training in quality aspects of MTS assay performance. Individual data from the six
laboratories that were trained, as well as the overall data of all laboratories (N; in bold and between
brackets) are included. Mean and SD (and SD*, in bold and between brackets) values of calculated
EC30 (nM staurosporine) and EC50 (µg/mL PS-NH2), coefficient of variation (CV) (%) and number of
runs (n) are given. For tier 2, data from all (valid and non-valid) runs and valid runs only are indicated.
Tier 3 data are presented in the presence and absence of cells. ‘-’ indicates that no data were available,
laboratory 6 participated only in tier 3.
EC30 Staurosporine (nM) EC50 PS-NH2 (µg/mL)
Laboratory Mean SD CV (%) Runs (n) Mean SD CV (%) Runs (n)
Before
training (tier 2)
All runs
1 539.9 63.7 11.8 2 83.7 12.1 14.4 8
2 421.3 218.6 51.9 16 82.2 26.8 32.5 9
3 275.0 79.4 28.9 7 75.6 9.2 12.2 4
4 171.4 28.9 16.9 10 62.7 10.2 16.2 5
5 129.4 2.4 1.8 4 69.4 10.5 15.1 2
6 - - - - - - - -
All labs 329.7(N = 15)
182.0
(SD*=78.7) 55.2 -
76.2
(N = 15)
20.4
(SD*=10.6) 26.8 -
Before
training (tier 2)
Valid runs
1 - - - - 75.9 28.1 37.0 3
2 303.4 159.9 52.7 6 - - - -
3 278.8 108.2 38.8 5 75.6 9.2 12.2 4
4 160.1 81.8 51.1 5 - - - -
5 - - - - - - - -
6 - - - - - - - -
All labs 261.0(N = 8)
121.1
(SD*=84.6) 46.4 -
76.2
(N = 4)
12.9
(SD* = 6.9) 16.9 -
After training
(tier 3)
Cells present
1 78.1 18.3 23.4 6 59.5 7.6 12.8 3
2 237.3 73.4 30.9 6 102.8 20.0 19.4 3
3 156.2 23.6 15.1 6 71.3 3.9 5.4 3
4 255.0 92.9 36.4 3 87.5 21.1 24.2 3
5 290.4 40.4 13.9 6 87.5 9.5 10.9 3
6 596.1 194.5 32.6 6 103.2 21.6 21.0 3
All labs 238.5(N = 6)
118.3
(SD*=59.4) 49.6 -
85.3
(N = 6)
19.7
(SD*=16.5) 23.0 -
After training
(tier 3)
Cells absent
1 82.9 11.1 13.4 6 56.9 4.7 8.2 3
2 267.2 71.4 26.7 6 104.5 0.2 0.2 3
3 162.0 21.5 13.3 6 70.5 4.8 6.9 3
4 320.2 90.9 28.4 3 64.1 9.5 14.8 3
5 284.6 29.4 10.3 6 85.3 8.9 10.4 3
6 581.8 143.9 24.7 6 102.6 30.7 29.9 3
All labs 264.3(N = 6)
140.0
(SD*=53.1) 53.0 -
80.7
(N = 6)
22.8
(SD* = 7.7) 28.2 -
When considering the entire data sets obtained in tier 2 (valid and non-valid runs) and tier 3 with
read-out of the MTS assay in the presence of cells, the inter-laboratory variability assessed by means of
CV (%) of all laboratories before (tier 2, N = 15) and after (tier 3, N = 6) training showed improvement
due to training (respectively 55.2% compared to 49.6% for staurosporine, and 26.8% compared to
23.0% for PS-NH2). Furthermore, the reproducibility within the laboratories was found to be increased
after training, which is obvious from the decrease in CV per laboratory (example of dose-response
curves in Figure S8), as well as the decrease of overall SD* in the case of staurosporine (Table 3).
Finally, reading out the MTS assay in the absence of cells resulted in a mean fitted EC30 of 264.3 ±
140.0 nM staurosporine and EC50 of 80.7 ± 22.8 µg/mL PS-NH2. Although this additional step did
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not further decrease the inter-laboratory variability (CV of all laboratories of 53.0% for staurosporine,
and 28.2% for PS-NH2), it did further improve intra-laboratory performances for most laboratories
as compared to cells present in the wells, evident again by decreased CV of individual laboratories
and SD* (Figure S6 vs. Figure S5, Figure S7, and Table 3). Taking into account also the fact that in
the second tier the majority of laboratories sent in non-valid run data (Table 1), because they were
ignorant of good practice and ILC principles, these comparative analyses show that training improved
the laboratories’ proficiencies and ILC results.
4. Discussion
Nanotoxicological data reported in the literature have shown low reproducibility within and
between different studies, and, consequently, conflicting conclusions. In the current ILC study, we
aimed to tackle this problem by introducing SOPs for cytotoxicity testing via the MTS assay, using
previously well characterized control NMs. In particular, we have evaluated the impact of training in
these SOPs and in good laboratory practices on the proficiency of the participating laboratories.
The ILC study was composed of three tiers, including cell culturing and cell growth rate
determination (tier 1), MTS assay for cytotoxicity measurement of NMs to evaluate the laboratories’
inherent performance (tier 2) and, finally, a repetition of the MTS assay after training of the laboratories
(tier 3). The process applied in this study has highlighted the degree of complexity that is related to
good practice in nanosafety testing, where multiple consecutive steps of the workflow should all be
tightly aligned, including material storage, NP dispersion, cell culture, cell seeding and exposure, and
test performance. This has also been concluded in a round robin study performed by different partner
laboratories of the German Priority Programme SPP1313, who observed that small variations in NP
preparation, cell handling and the type of culture slide influenced NP stability and the outcomes of cell
assays [57]. In another ILC study on the MTS cytotoxicity assay [34], system control measurements
revealed similar steps in the protocol that are critical to ensure overall robustness and reproducibility
of the assay results within and between laboratories. These factors have also been taken into account
in ISO 19007:2018(E) [37].
In contrast to previous interlaboratory studies in the nanosafety research field, we here
demonstrated that the availability of an optimized SOP in combination with training and the active
implementation of good practice in test performance enhanced the quality of intra-laboratory test
results, and improved inter-laboratory variability. The ILC study has also highlighted that principles
of GLP, including the use of verified instruments and registration of each step in the execution, may
provide guidance to enhance quality of results from in vitro toxicity assays. The developed SOPs
for cell culture, cell growth rate determination and the MTS assay for the cytotoxicity assessment of
NMs, were compiled to cover the different categories of test facility activities, including equipment,
media and reagents, test and control items, the consecutive steps of the experimental protocol in a
chronological order and data analysis. Furthermore, the SOPs included acceptance criteria to monitor
test performance, forms to record the laboratory performance and observations, and calculation
templates for the reporting of the test data. Each of these categories contained sufficient and explicit
detail to ensure proper execution. Based on feedback collected from the participating laboratories
through an online survey, however, we found that despite the availability of SOPs, deviations in the
execution were frequently reported, for example, in the verification of laboratory instruments or the
addition of antibiotics to the cell culture medium. Additionally, basic laboratory practices, such as
pipetting techniques, which are not normally made explicit in SOPs were identified as a potential
source of variability, in addition to influences from differences in technical infrastructure. This overall
complexity accounts for the conflicting results on NPs’ toxicity in the reported literature, and calls for
increasing awareness and proper training of nanosafety professionals. Based on the feedback received
after the second tier, the MTS assay SOP was revised to account for the identified hidden sources of
variability, and additional training was provided to ensure all participating laboratories were familiar
with the procedures and carefully followed all steps as detailed in the SOP. The results of the second
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ILC on the MTS assay showed that this process makes it possible to obtain higher reproducibility
across independent laboratories from academia, research institutions and industry. The NIEHS Nano
GO Consortium [33] has previously investigated NMs in several bioassays, including the MTS assay.
They also found substantial variations in the results between different laboratories, and further stated
that “frequent communication was very helpful for achieving reproducible results within and among
the laboratories”. However, no further details regarding the improvement of reproducibility were
given. As similar issues related to the quality in test performance discussed in our study are also
present among different operators within the same laboratory, it may be valuable to implement a
similar process using shared materials as described here within laboratories, to determine and align
the reproducibility in performance by multiple operators. A representative selection of positive and
negative control materials, as well as SOPs with quality acceptance criteria and statistical data analysis,
will make it possible to judge whether the data generated by multiple operators, even within a single
laboratory, are reliable or not.
As a secondary outcome of this ILC study, we confirmed the suitability of PS-COOH and PS-NH2
as negative and positive control nanomaterials, respectively, to validate the test performance of the MTS
assay. The PS-COOH NPs are complementary to other suggested negative nano-sized control materials
for in vitro cell viability assays, such as barium sulfate [44] and carboxylated nanodiamonds [45].
Positively charged PS-NH2 NPs have already been included as validated positive control nanomaterials
in the ISO 19007:2018(E) standard [37]. Based on the dose-response data obtained for the PS-NH2 in
our large ILC study comprising a representative sample of research laboratories, an EC50 value of
80.7 ± 22.8 µg/mL was obtained which is exactly within the commonly accepted biological variability
window of CV <30%. This EC50 for PS-NH2 was higher than the consensus EC50 value of 52.6 µg/mL
(95% confidence intervals 44.1 to 62.6 µg/mL) for the same NPs in the A549 cell line reported by
Elliott et al. [34], which can be attributed to differences in cell stocks, serum sources, cell seeding
density and exposure times (24 vs. 48 h, respectively). Nevertheless, variability in the EC50 values in
both studies was in a similar range and well below 30%, confirming the suitability of 50-nm PS-NH2 as
positive control NPs in the MTS cytotoxicity assay. However, it should be mentioned that, in both
studies, PS-NH2 from Bangs Laboratories Inc. have been used, which were not available anymore
from the supplier at the time of this report. Therefore, to enable standardization in nanosafety testing,
stable and effective reference NPs from a secured source are urgently needed.
We also stress that for this study, in order to focus—as a first step—on the sources of variability
related to cell toxicity testing, we selected model PS NPs behaving well in terms of stability and
dispersion, thus, many of the reproducibility issues highlighted in our study are not nano-specific.
Reproducibility in in vitro nanotoxicity testing goes far beyond this simplistic view, as real nanoparticles,
such as, for instance, metal oxides, introduce many more challenges related to their intrinsic (medium
independent) and extrinsic (medium dependent) physical and chemical properties, which affect
their dispersion and stability in cell culture medium, and—as a consequence of this—their fate and
transport into cells, and, thus, the dose delivered to cells as a function of exposure time [58,59].
For example, surface affinity, which is dependent on particle and medium parameters, may cause
the agglomeration or aggregation of nanomaterials, whereas particle size and density can affect the
diffusion and sedimentation of NPs, thus affecting their in vitro exposure. Furthermore, especially
for partially soluble NPs, such as metal and metal oxides, the rate of release of ions is depending on
system parameters (e.g., pH, ligands present, flow conditions, etc.) and can greatly influence their
in vitro toxicity potential. To allow for the correct interpretation of in vitro assay data using NPs
closer to real applications, as opposed to model NPs with optimal dispersibility, standard protocols
for the dispersion of nanomaterials in complex media, dispersion characterization and dosimetry, as
described by Deloid et al. [59] and in ISO/TR 16196:2016 [60], should be adopted to ensure meaningful
and reproducible quantification of in vitro delivered dose. The standardization of characterization
methods to monitor the physicochemical properties before and after NPs’ dispersion is also work in
progress, e.g., by the OECD Series on the Safety of Manufactured Nanomaterials [58] and ISO/TC229
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(Nanotechnologies), and has been subject of several ILC studies. Remarkably, in ILC studies in which
model nanoparticles as polystyrene, gold or silica nanospheres have been used, for example those
looking at size distribution measurements using nanoparticle tracking analysis [61], dynamic light
scattering and centrifugal particle sedimentation [49], similar issues in reproducibility compared to
our study have been reported, even for simple dispersions in buffer. They concluded that SOPs are
indispensable for obtaining reliable and comparable NP size data, and should be tailored to the specific
test system, sufficiently detailed and verified by a larger number of laboratories, to enable reproducible
performance [49,61].
Other NP types than polystyrene have already been applied by others in the MTS assay, such as
titanium dioxide, zinc oxide and multi-walled carbon nanotubes [33]. In addition to selecting the best
protocol for NPs’ dispersion and verification of the dispersion stability in complete CCM, as indicated
above, these will require a case-by-case consideration of interference of the NPs with the optical density
measurements. Although, initially, a number of laboratories observed optical interference of PS-NH2
with the MTS test read-out in our study (tier 2), we showed that, after good practice training and
diligent application of the optimized SOP, this bias was resolved. This may be attributed to detailed
instructions on NP dispersion in serum-containing medium and the use of the same serum batch by all
laboratories. In addition, we introduced in the SOP a transfer of MTS medium to a new plate before
optical read-out to avoid high absorbance contribution of the cells and NPs remaining in the wells.
In this respect, our SOP deviates from the ILC study of Elliott et al. [34] and the ISO 19007:2018(E)
standard [37], in which the average background absorbance level of the NP doses in culture medium
are subtracted from each absorbance value of NP-exposed cells. In contrast, we recommend using an
alternative cytotoxicity assay, based on a different optical read-out principle, in case NP interference
is observed, as the correct assessment of the issue and adjustment is hampered by multiple factors,
such as NP agglomeration, NP adherence to the cell surface or assay plate, cell-dependent NP uptake
kinetics, etc.
Finally, it remains to be investigated whether the MTS assay SOP developed and tested by multiple
laboratories in our study can be transferred to other cell types. Based on our experience, the SOP
works optimally for adherent cell types growing in monolayers. The SOP can be adapted for use with
suspension cells by introducing centrifugation steps to pellet the cells at the bottom of the wells before
medium changes.
In conclusion, the experience reported in this study overall clearly indicates that the approach
followed in this study, including inter-laboratory comparison studies using shared materials and
detailed SOPs, together with training of the participants, can be used to optimize and generate robust
SOPs, and to obtain reproducible data on NP cytotoxicity within and across independent laboratories.
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